PriceTargets.com logo

Aerovate Therapeutics - AVTE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.25
  • Forecasted Upside: -12.11%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.56 As of 12/17/2024 06:26 PM ET
+0 (0.00%)

This chart shows the closing price for AVTE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aerovate Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVTE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVTE

Analyst Price Target is $2.25
▼ -12.11% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Aerovate Therapeutics in the last 3 months. The average price target is $2.25, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a -12.11% upside from the last price of $2.56.

This chart shows the closing price for AVTE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Aerovate Therapeutics. This rating has held steady since May 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/18/2024Evercore ISIDowngradeOutperform ➝ Inline$27.00 ➝ $2.00
6/18/2024TD CowenDowngradeBuy ➝ Hold
6/18/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$35.00 ➝ $2.00
6/17/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$65.00 ➝ $2.00
6/17/2024GuggenheimReiterated RatingBuy ➝ Neutral
6/17/2024BTIG ResearchDowngradeBuy ➝ Neutral
6/17/2024WedbushDowngradeOutperform ➝ Neutral$41.00 ➝ $3.00
6/6/2024WedbushReiterated RatingOutperform ➝ Outperform$41.00 ➝ $41.00
5/22/2024WedbushReiterated RatingOutperform ➝ Outperform$41.00
5/14/2024WedbushReiterated RatingOutperform ➝ Outperform$41.00
4/4/2024WedbushReiterated RatingOutperform
4/1/2024Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight$35.00
3/25/2024Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$21.00 ➝ $65.00
12/8/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$35.00
11/14/2023WedbushReiterated RatingOutperform$48.00
8/15/2023WedbushReiterated RatingOutperform$50.00 ➝ $48.00
2/28/2023GuggenheimInitiated CoverageBuy$36.00
12/12/2022WedbushBoost Target$27.00 ➝ $54.00
12/6/2022BTIG ResearchUpgradeNeutral ➝ Buy$27.00
9/19/2022WedbushReiterated RatingOutperform$27.00
8/17/2022WedbushReiterated RatingOutperform
8/16/2022BTIG ResearchDowngradeBuy ➝ Neutral
3/31/2022WedbushReiterated RatingOutperform$23.00
2/11/2022BTIG ResearchInitiated CoverageBuy$24.00
11/16/2021WedbushReiterated RatingBuy$22.00
7/26/2021Evercore ISIInitiated CoverageOutperform
7/26/2021CowenInitiated CoverageOutperform
7/26/2021Jefferies Financial GroupInitiated CoverageBuy$21.00
7/25/2021WedbushInitiated CoverageOutperform$23.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.45 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 5 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aerovate Therapeutics logo
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $2.56
Low: $2.52
High: $2.63

50 Day Range

MA: $2.49
Low: $2.04
High: $2.79

52 Week Range

Now: $2.56
Low: $1.25
High: $32.42

Volume

92,236 shs

Average Volume

581,115 shs

Market Capitalization

$73.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Aerovate Therapeutics?

The following Wall Street sell-side analysts have issued reports on Aerovate Therapeutics in the last twelve months: BTIG Research, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., TD Cowen, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for AVTE.

What is the current price target for Aerovate Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aerovate Therapeutics in the last year. Their average twelve-month price target is $2.25, suggesting a possible downside of 12.1%. Wedbush has the highest price target set, predicting AVTE will reach $3.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $2.00 for Aerovate Therapeutics in the next year.
View the latest price targets for AVTE.

What is the current consensus analyst rating for Aerovate Therapeutics?

Aerovate Therapeutics currently has 6 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AVTE, but not buy more shares or sell existing shares.
View the latest ratings for AVTE.

What other companies compete with Aerovate Therapeutics?

Other companies that are similar to Aerovate Therapeutics include COMPASS Pathways, Foghorn Therapeutics, AC Immune, Amylyx Pharmaceuticals and Lifecore Biomedical. Learn More about companies similar to Aerovate Therapeutics.

How do I contact Aerovate Therapeutics' investor relations team?

The company's listed phone number is 617-443-2400 and its investor relations email address is [email protected]. The official website for Aerovate Therapeutics is aerovatetx.com. Learn More about contacing Aerovate Therapeutics investor relations.